Trial Profile

A Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of BL-M07D1 for Injection in Patients With Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BL-M07D1 (Primary)
Indications Biliary cancer; Carcinoma; Gastrointestinal cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Sichuan Baili Pharmaceutical

06 Mar 2024 Status changed from not yet recruiting to recruiting.
30 Jan 2024 Planned End Date changed from 1 Nov 2025 to 1 Mar 2026.
30 Jan 2024 Planned primary completion date changed from 1 Nov 2025 to 1 Mar 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com